Search Results
488 results found for "Cost-efficient medications https://simplemedrx.top"
- ANAVEX 2-73 Shown to Block Oxidative Stress, Preventing Onset of Alzheimer's Disease
Full details of the study are described on Anavex’s website at https://anavex.com//files/2012-10-17_ANAVEX Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex to Present at Neuroscience 2012 in New Orleans
Additional information is available at http://www.sfn.org/am2012/home.aspx. Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Recognizes Alzheimer's Action Day
Early detection can help individuals get the most effectiveness from currently available treatments and Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Presents Compelling Data at World's Largest Alzheimer's Conference
Montpellier and by Anavex Life Sciences Corp., details of the study are described on Anavex’s website https Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex to Present at Alzheimer's Association International Conference
Additional information about the conference is available at http://www.alz.org/aaic/. Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Robert Chisholm as CFO
His financial expertise is exactly what the company needs as we work to improve operational efficiency Chisholm served as CFO for PNI Digital Media (formerly PhotoChannel Networks Inc.) and subsequently joined Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Comments on President Obama's National Plan to Fight Alzheimer's Disease
About Alzheimer’s While Alzheimer’s is most common in people over the age of 65, it can strike adults Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Successfully Completes a Phase 1 Clinical Trial for ANAVEX 2-73
About Alzheimer’s Disease While Alzheimer’s Disease is most common in people over the age of 65, it can Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Dr. George Tidmarsh as Executive Director
Most recently, Dr. Tidmarsh’s background includes various positions at Coulter Pharmaceuticals, including Chief Medical Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Announces Director Resignation
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex to Present Data on ANAVEX 2-73, Lead Compound for Alzheimer's Disease
(“Anavex”) (OTCBB: AVXL) will present the most recent data showing the therapeutic potential of ANAVEX The most recent data suggested that ANAVEX 2-73 could alleviate the generation of newly formed amyloid-beta About Alzheimer’s Disease While Alzheimer’s disease is most common in people over the age of 65, it can Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Presents Data on Neuroprotective Evidence for ANAVEX 2-73, Lead Compound for AD
these compounds could be compared to donepezil, which is the market leader in Alzheimer’s disease (AD) medication The posters are available on the Anavex web site: https://anavex.com//files/AAIC_Poster_Tangui_July_2011 .pdf and https://anavex.com//files/AAIC_Poster_Tangui_tau_July_2011.pdf. About Alzheimer’s Disease While Alzheimer’s disease is most common in people over the age of 65, it can Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
